Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs) Webinar Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs) Certara2026年2月23日
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development Blog FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…Certara2026年2月18日
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Guide Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…Certara2026年2月13日
Pediatric Drug Development: From “Wild West” to Model-Informed Confidence Blog From “Wild West” to Model-Informed Confidence Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…Certara2026年2月11日
Why Many Global Drugs Never Reach Japan Press Coverage Why Many Global Drugs Never Reach Japan Despite faster reviews, many global drugs never reach Japan. Learn how early development decisions, trial…Certara2026年2月5日
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants Publication Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…Certara2026年2月2日
Opinion: To Accelerate Rare Disease Progress, Take a Sandbox Approach Press Coverage Opinion: To Accelerate Rare Disease Progress, Take a Sandbox Approach Explore how a collaborative “sandbox” approach—combining flexible regulation, data modeling, and stakeholder engagement—can transform rare…Certara2026年1月30日
P21 Enterprise Expands Regulatory Validation Capabilities with Support for the Tobacco Implementation Guide v1.0 Blog P21 Enterprise Expands Regulatory Validation Capabilities with Support for the Tobacco Implementation Guide v1.0 Pinnacle 21 supports TIG v1.0, the CDISC Tobacco Implementation Guide for FDA CTP, enabling automated…Certara2026年1月30日
How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most Blog How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…Certara2026年1月26日
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients Publication Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…Certara2026年1月22日